Drug Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Benign Prostatic Hyperplasia

BXL628 arrests prostate growth in patients with benign prostatic hyperplasia

Researchers in Italy conducted a study "to evaluate the effect of BXL628, a vitamin D3 analog, on prostate volume in patients with BPH. We conducted a phase II, double blind, randomized, placebo controlled, clinical study. Patients eligible were aged {{>=}}50 years, had a diagnosis of BPH and a prostate volume {{>=}}40 ml."

E. Colli and colleagues from the Università Vita Salute San Raffaele wrote, "Eligible patients were randomized and given either BXL628 150 mcg daily or placebo for 12 weeks. All randomized patients underwent at...

• View Other Issues of Drug Week
  
• View Other NewsRx Publications